In the realm of pharmaceuticals, a recent partnership between Zentiva Group and Lupin has been making waves in the industry. The two companies have joined forces in a license and supply agreement centered around Lupin’s biosimilar Certolizumab Pegol, a potent tumour necrosis factor alpha (TNFα) inhibitor medication. This strategic alliance is poised to significantly increase the availability of this vital biosimilar on a global scale.
The collaboration entails Zentiva taking charge of commercial activities primarily in Europe and CIS markets, excluding the US and Canada. On the other hand, Lupin will be entrusted with product development, manufacturing, and supplying the medicine within specific territories while also spearheading commercial efforts in other regions, including Canada and the US.
“This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions.”
– Fabrice Egros, Lupin President of Corporate Development
One of the key highlights of this venture is that both Lupin and Zentiva are committing substantial investments into this endeavor. Lupin stands to receive an initial $10 million upon signing the agreement, with the potential to earn up to $50 million based on achieving various developmental and regulatory milestones along the way.
Furthermore, profits generated within their respective markets will be shared between Zentiva and Lupin—a testament to their collaborative spirit aimed at mutual success.
Steffen Saltofte, CEO of Zentiva Group, emphasized their commitment to providing accessible healthcare by stating:
“Ensuring accessibility to high-quality and affordable healthcare is at Zentiva’s core.”
The biosimilar itself is no ordinary drug; it boasts a unique composition as a recombinant humanized antibody Fab’ fragment targeting TNFα that is conjugated to a 40kDa polyethylene glycol—an innovative approach in biopharmaceuticals.
With indications covering various conditions such as rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease among others; this biosimilar holds promise for patients grappling with these challenging health issues.
“Our collaboration agreement with Lupin signifies another step forward in our biosimilars and growth strategies.”
– Steffen Saltofte
Moving beyond just business interests, there is an underlying ethos driving this partnership—both companies share a common goal of enhancing healthcare access globally while focusing on affordability without compromising quality standards.
Fabrice Egros from Lupin reiterated this sentiment by stating:
“Our partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions.”
This deal comes hot on heels as earlier in March 2025; Lupin had struck another licensing agreement concerning its biosimilar ranibizumab with SteinCares directed towards Latin American markets but excluding Argentina and Mexico.
In conclusion,
the collaboration between Lupin
and Zentiva represents not only
a significant business venture
but also embodies a shared commitment
towards improving healthcare access
and affordability worldwide.
Together they are paving
the way for better treatment options
for patients battling chronic illnesses,
ushering in a new era
of hope and healing through innovation.
